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Summary
Background: Tumor cells can move in a three-dimensional
(3D) environment in either mesenchymal-type or amoeboid
modes. In mesenchymal-type movement, cells have an elon-
gated morphology with Rac-induced protrusions at the lead-
ing edge. Amoeboid cells have high levels of actomyosin
contractility, and movement is associated with deformation
of the cell body through the matrix without proteolysis.
Because signaling pathways that control the activation of
GTPases for amoeboid movement are poorly understood, we
sought to identify regulators of amoeboid movement by
screening an siRNA library targeting guanine nucleotide
exchange factors (GEFs) for Rho-family GTPases.
Results: We identified DOCK10, a Cdc42 GEF, as a key player
in amoeboid migration; accordingly, we find that expression of
activated Cdc42 induces a mesenchymal-amoeboid transition
and increases cell invasion. Silencing DOCK10 expression
promotes conversion to mesenchymal migration and is asso-
ciated with decreased MLC2 phosphorylation and increased
Rac1 activation. Consequently, abrogating DOCK10 and
Rac1 expression suppresses both amoeboid and mesenchy-
mal migration and results in decreased invasion. We show
that the Cdc42 effectors N-WASP and Pak2 are required for
the maintenance of the rounded-amoeboid phenotype. Block-
ing Cdc42 results in loss of mesenchymal morphology, arguing
that Cdc42 is also involved in mesenchymal morphology
through different activation and effector pathways.
Conclusions: Previous work has identified roles of Rho and
Rac signaling in tumor cell movement, and we now elucidate
novel roles of Cdc42 signaling in amoeboid and mesenchymal
movement and tumor cell invasion.
Introduction
Recent studies of cell migration in three dimensions have led to
a reassessment of the mechanisms that mediate tumor cell mo-
tility. In collagen gels, cell-derived matrices, slice cultures, and
in vivo, cell movement and morphology may differ markedly
from that seen on rigid planar substrata. A major difference
between two-dimensional (2D) and three-dimensional (3D) en-
vironments is that in 3D, some tumor cells adopt an amoeboid
form of movement that is not evident in 2D [1, 2]. Amoeboid
movement is characterized by a rounded, blebbing morphol-
ogy, independence from extracellular proteases, and a require-
ment for high levels of actomyosin contractility downstream of
*Correspondence: chris.marshall@icr.ac.ukRhoA-ROCK signaling to deform the extracellular matrix and
propel cell movement [3–6]. Studies with intravital microscopy
show that amoeboid movement of tumor cells can be very rapid
in vivo (w5 mm/min [7]). In contrast, mesenchymal-type move-
ment can be seen in both 2D and 3D environments and is
characterized by an elongated morphology, resulting from
Rac-dependent actin assembly at the leading edge. These
two modes of movement are interconvertible so that tumor
cells may undergo amoeboid-mesenchymal and mesenchy-
mal-amoeboid transitions [1, 4, 5]. This plasticity may permit
adaptation of modes of migration in different environments.
Rho-family GTPases are key players in the signaling events
for cell movement. Rac1 drives motility by promoting lamellipo-
dium formation and cell protrusions [8]. RhoA signaling
activates the ROCK family of kinases, promoting actin stress-
fiber formation and generation of the actomyosin contractile
force required for retraction of the rear of the cell in mesenchy-
mal-typemovement [9, 10]. High levels of RhoA-ROCKsignaling
generate cortical actin assembly and high levels of actomyosin
contractility in amoeboid movement [3, 4]. Cdc42 is activated at
the leading edge of lamellipodia and is required for Arp2/3-
dependent actin assembly [11]. Cdc42 activation may also be
required for Rac activation [12, 13]. In addition, Cdc42 has
been shown to be important in generating directionality during
mesenchymal movement through polarizing microtubules
[14]. Although Cdc42 has been shown to be involved in cell
motility in 2D, its role in 3D motility has not been investigated.
The regulation of Rho-family GTPase activity during cell
movement is poorly understood. Guanine nucleotide ex-
change factors (Rho-family GEFs) control the activation of
Rho-family GTPases [15], whereas GTPase-activating proteins
(Rho-family GAPS) control inactivation. The human genome
contains approximately 83 GEFs that fall into three subfam-
ilies. The largest set is the DH-PH-containing proteins with
Dbl as the prototype [16]; the DH domains mediate GEF activ-
ity, and the PH domains have an autoinhibitory role and may
mediate membrane recruitment [17–19]. Rac, Rho, and
Cdc42 have all been shown to be activated by DH-PH-domain-
containing GEFs. Most members of the DH-PH family contain
other interaction domains that connect the GEFs to signaling
partners and cellular activities. Related to the DH-PH family
is the small family of SWAP-70-related proteins in which
a PH domain precedes a DH domain.
The second major class of GEFs is the DOCK family; these
lack DH and PH domains, and exchange factor activity is
mediated by DHR2 domains [20, 21]. Members of this family
have high molecular mass (w200 kDa) and contain a second
conserved domain, termed DHR1 [20, 21]. Unlike DH-PH-family
GEFs, DOCK-family proteins are found in yeasts and plants as
well as animals [20, 21]. DOCK-family members activate either
Rac or Cdc42, and to date no member has been associated
with Rho activation. DOCK180, as well as DOCK2 and
DOCK3, activate Rac to regulate cell adhesion, cell spreading,
migration, and phagocytosis [22–24]. The zizimin subfamily
consists of three genes named zizimin1/DOCK9, zizimin2/
DOCK11, and zizimin3/DOCK10. DOCK9 and DOCK11 are
very similar and are exchange factors for Cdc42, but their tissue
distribution in mice is different: DOCK9 is predominantly
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1457Figure 1. Cdc42 GEF DOCK10 Is Required for Rounded Morphology and Amoeboid Motility of A375M2 Melanoma Cells
(A) Still pictures taken at 24 hr of A375m2 cells stably expressing control or shRNA DOCK10 plated on thick collagen I in 1% serum and imaged with time-
lapse phase-contrast microscopy (scale bar represents 100 mm). The inset numbers show the percentage of cells with elongated morphology (>100 cells
scored per experiment, n = 5, mean 6 SEM).
(B) Immunoblot showing knockdown of DOCK10.
(C) Levels of total and active GTP-bound Cdc42 from cells plated on a thick layer of collagen I. One representative experiment out of three is shown.
(D) Immunoblot for p-T18-S19-MLC2. One representative experiment out of three is shown.
(E) A375p cells expressing GFP-DOCK10DHR2 or GFP, plated on a thick layer of collagen I or embedded in collagen I in IBIDI chambers for 16 hr in 1%
serum. IBIDI chambers were imaged with time-lapse phase-contrast microscopy for 3 hr. The inset numbers show the percentage of cells with elongated
morphology (>100 cells scored per experiment, n = 3, mean 6 SEM).
(F) Immunoblot for p-T18-S19-MLC2. One representative experiment out of three is shown.expressed in nonhematopoietic cells, and DOCK11 is predom-
inantly expressed in lymphocytes [20, 25]. DOCK10 seems to
be more widely expressed in mice, overlapping both DOCK9
and DOCK10 expression patterns, and appears to bind with
a lower affinity to Cdc42 [25]. Interestingly, DOCK11 has been
shown to mediate a positive feedback activation of Cdc42 [26].
Because nothing is known about the mechanisms underly-
ing the activation of Rho-family GEFs in amoeboid movement,
we set out to identify Rho-family GEFs required for amoeboid
movement. Using siRNAs targeting 83 human Rho-family
GEFs, we identified human DOCK10 acting in the regulation
of amoeboid motility. This GEF is specific for amoeboid move-
ment because when its expression is abrogated, cells undergoan amoeboid-mesenchymal transition. DOCK10 targets
Cdc42, and we show that the Cdc42 effectors N-WASP and
Pak2 are required for amoeboid movement.
Results
Cdc42 GEF DOCK10 Is Required for Rounded Morphology
and Amoeboid Motility of A375M2 Melanoma Cells
Amoeboid migration has been reported to be dependent on
Rho-ROCK signaling and is associated with highly dynamic
membrane blebbing driven by actomyosin contractility [4, 5,
27]. To identify GEFs that activate Rho-family GTPases re-
quired for amoeboid movement, we screened a library of siRNA
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available online) for their effects on amoeboid movement of
A375M2 melanoma cells [4]. We used Dharmacon ‘‘SMART
pools’’ in which each gene is targeted by siRNAs directed
against four different sequences. The morphology and behav-
ior of transfected cells was assessed on top of a thick layer of
collagen I. In this assay, the majority of A375M2 cells have
a rounded morphology with very dynamic blebbing plasma
membranes, just as they do when they have invaded into
a 3D collagen I matrix (Movie S1). This system therefore pro-
vides a way to screen for genes affecting membrane blebbing,
cell morphology, and movement. Pools of siRNAs against five
GEFs led to decreases in the number of cells with a rounded
morphology and an increased proportion of elongated cells in
three independent experiments (Figure S3A). Of these, Vav1
was not found to be expressed in A375M2 cells, whereas
MCF2L2 and DOCK9 did not confirm with an independent set
of siRNAs and appear to be off-target effects. Of the remaining
two ‘‘hits,’’ DOCK6 and DOCK10, we focused on DOCK10 be-
cause it appeared to be involved in Cdc42 signaling [25] and
the role of Cdc42 in amoeboid movement has not been studied
[28]. Silencing DOCK10 with either the screening pool or five
siRNAs targeting different regions of DOCK10 consistently re-
sulted in cells adopting an elongated, polarized morphology
and moving in a mesenchymal manner with long protrusions
(Figures S3B and S3C). We also generated cell lines with stable
knockdown of DOCK10 through expression of shRNAs that
target different sequences from those used in the screen
(Figure S3D). In two different DOCK10 shRNA cell lines
(shDOCK10#2 and shDOCK10#3), the percentage of cells
with elongated-mesenchymal morphology was 27% 6 10%
(p value % 0.04) and 31% 6 14% (p value % 0.03) compared
Figure 2. Simultaneous Blockade of DOCK10
and Rac Inhibits Tumor Cell Invasion
(A) Invasion into collagen I by A375M2 cells trans-
fected with DOCK10, Rac1 siRNAs, or both
together (n = 3, mean 6 SEM). Knockdown of
DOCK10 and Rac1 were estimated by Q-PCR.
(B) Levels of active GTP-bound Rac1 from control
and DOCK10 knockdown A375m2 stable cell
lines plated on top of a thick layer of collagen I
(n = 3, mean 6 SEM).
(C) Levels of active GTP-bound RhoA from cells
on collagen I as for (B) (n = 3, mean 6 SEM).
to 12% 6 6% of elongated cells in the
shRNA control cell line (Figure 1A and
Movie S2). Figure 1B shows that
DOCK10 protein levels are approxi-
mately 50% reduced in these cell lines.
Tracking the motility of these elongated
cells showed that they moved at
0.211 6 0.026 mm/min (p value % 0.01)
and 0.264 6 0.031 mm/min (p value
% 0.01) compared with 0.109 6 0.008
mm/min for cells with a rounded morphol-
ogy in A375M2 control populations.
These results suggest that DOCK10 is
required to maintain a rounded morphol-
ogy and that loss of DOCK10 converts
amoeboid movement to elongated-mes-
enchymal type. Screening a panel of mel-
anoma cell lines shows that DOCK10
RNA is widely expressed but has a more variable expression
than related family members DOCK9 and DOCK11
(Figure S4). Simultaneous knockdown of DOCK9, DOCK10,
and DOCK11 produced no additional increase in the proportion
of elongated cells over DOCK10 alone, arguing that DOCK10
acts nonredundantly (data not shown).
DOCK10 is a member of the zizimin subfamily in which
DOCK9 and DOCK11 have been shown to be GEFs for
Cdc42 [25, 29]. Therefore, we investigated Cdc42 activity in
shRNA DOCK10 cell lines; Cdc42-GTP levels are decreased
compared to those of control cell lines (shDOCK10#2: 0.67 6
0.14-fold decrease, p value% 0.02 and shDOCK10#3: 0.61 6
0.13-fold decrease, p value % 0.01), suggesting that
DOCK10 acts as a Cdc42 GEF in vivo (Figure 1C). GEFs form
stable complexes with their cognate GTPase in the nucleo-
tide-free state, and we confirmed existing data indicating
that DOCK10 binds to nucleotide-depleted Cdc42 but not
Rac or Rho (Figure S5) [25]. Taken together, the observations
that knockdown of DOCK10 results in decreased Cdc42-GTP
and that DOCK10 binds nucleotide-free Cdc42 strongly argue
that DOCK10 is a Cdc42 GEF.
High levels of phosphorylation of myosin light chain 2
(MLC2) are a feature of amoeboid motility [5]; therefore, we
used phosphorylation of MLC2 as a biochemical marker of
amoeboid behavior. As shown in Figure 1D, the knockdown
of DOCK10 resulted in decreased MLC2 phosphorylation com-
pared to control (shDOCK10#2: 0.74 6 0.13-fold decrease,
p value % 0.03 and shDOCK10#3: 0.66 6 0.19-fold decrease,
p value % 0.04), showing that DOCK10 signaling leads to
elevated MLC2 phosphorylation.
Because abrogation of DOCK10 expression in A375M2 cells
results in loss of amoeboid motility, we investigated whether
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1459Figure 3. Activated Cdc42 Converts Mesenchymal-Type A375p Cells to Rounded Morphology and Increases Invasion
(A) Immunoblot of Cdc42 in A375p cells overexpressing Cdc42QL.
(B) Still pictures at end of 3 hr time-lapse video sequence of control or A375p cells stably expressing Cdc42-QL embedded in collagen I in IBIDI chambers
(scale bar represents 100 mm). Arrows point to elongated cells. The inset numbers show the percentage of cells with elongated morphology (>100 cells
scored per experiment, n = 3, mean 6 SEM).
(C) Immunoblot for p-T18-S19-MLC2 from cells plated on a thick layer of collagen I. One representative experiment out of three is shown.
(D) Invasive properties of A375p cells expressing HA-tagged Cdc42-QL or control (n = 3, mean 6 SEM).overexpressing DOCK10 in a mesenchymal-type cell line
would lead to a rounded-amoeboid morphology. A375M2 cells
were derived from A375p melanoma cells [30] that have
a much higher proportion of elongated-mesenchymal cells
with protrusions than A375M2 cells when plated on a thick
layer of collagen I (50% 6 7% elongated cells versus 12% 6
6% for A375M2). When an N-terminally-truncated version of
DOCK10 that retains the exchange factor DHR2 domain was
expressed in A375p cells, the percentage of elongated-
mesenchymal cells dropped dramatically to 12% 6 10%
(p value % 0.02) (Figure 1E). Consistent with the acquisition
of a rounded-amoeboid morphology, expression of
DOCK10DHR2 led to a strong increase in pMLC2 (Figure 1F).
These data suggest that DOCK10 through increasing MLC2
phosphorylation can drive a rounded-amoeboid morphology.
Blocking DOCK10 and Rac1 Inhibits Tumor Cell Invasion
To examine the role of DOCK10 in invasion, we examined inva-
sion into a 3D collagen I matrix. Figure 2A shows that knock-
down of DOCK10 enhanced invasion by 3.27 6 0.42-fold
(p value%0.01). This was somewhat surprising, however, given
that we have observed that loss of DOCK10 resulted in in-
creased motility of A375M2 cells with elongated-mesenchy-
mal-type morphology. We investigated whether the increased
invasion resulted from elevated levels of activated Rac1 that
then drives mesenchymal-type movement. Figure 2B shows
that when DOCK10 expression is reduced, there is increased
Rac1-GTP compared to control (shDOCK10#2: 1.78 6 0.29-fold increase in Rac-GTP, p value % 0.04 and shDOCK10#3:
1.90 6 0.12-fold increase, p value % 0.01). The increased
Rac1 activation was associated with reduced activation of
RhoA (Figure 2C; shDOCK10#2: 0.76 6 0.07-fold decrease in
RhoA-GTP, p value % 0.02 and shDOCK10#3: 0.73 6 0.02-
fold decrease, p value%0.002); suchan inverse relationship be-
tween Rac and Rho activity is well known [31]. Given these re-
sults, we tested whether the increased invasion in DOCK10
knockdown cells was dependent on Rac1. Silencing Rac1 and
DOCK10 together abrogated the increase in invasion seen onsi-
lencing DOCK10 (0.56 6 0.08-fold decrease compared to con-
trol, p value% 0.01). These results argue that in cells such as
A375M2 that can interconvert between amoeboid and mesen-
chymal movement, DOCK10 and Rac1 act in different path-
ways. When DOCK10 cannot promote amoeboid movement,
cells adopt Rac-dependent mesenchymal movement.
Activated Cdc42 Converts Mesenchymal-Type A375p
Cells to Rounded Morphology and Increases
Amoeboid Cell Movement and Invasion
These results suggest that activation of Cdc42 can lead to
amoeboid motility and tumor cell invasion. Therefore, we ex-
amined whether expression of a constitutively active Cdc42
mutant (Cdc42-QL) in A375p cells would lead to conversion
to a rounded morphology. Two different pools of cell lines
with different levels of expression were isolated (Figure 3A).
Cdc42-QL overexpression led to a higher proportion of cells
with a rounded phenotype [Cdc42QL(3): 30% 6 13%
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1460Figure 4. Cdc42 Effectors N-WASP and Pak2 Are Required for Rounded Morphology
(A) A375M2 cells transfected with control or N-WASP siRNAs plated on a thick layer of collagen I for 16 hr in 1% serum were time-lapsed for 24 hr. Still
pictures from the end of the sequences are presented (scale bar represents 100 mm). The inset numbers show the percentage of cells with elongated
morphology (>100 cells scored per experiment, n = 5, mean 6 SEM).
(B) Coimmunoprecipitation of DOCK10 and N-WASP in WM1366. DOCK10 was immunoprecipitated with antibodies A301-305A (recognizing epitopes in aa
100–150) or A301-306A (aa 2136–2186) and immunoprecipitates blotted for N-WASP.
(C) Phase-contrast pictures from control or shPAK2 A375m2 cells plated on a thick layer of collagen I (scale bar represents 100 mm). The inset numbers show
the percentage of cells with elongated morphology (>100 cells scored per experiment, n = 3, mean 6 SEM).
(D) Immunoblots for Pak2 and p-T18-S19-MLC2. One representative experiment out of three is shown.
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elongated cells, p value % 0.03] compared to control A375p
cells (47% 6 15% elongated cells). Similar results were ob-
tained with cells embedded in collagen I (Figure 3B and Movies
S3 and S4). Figure 3C shows that these morphological
changes were associated with increased MLC2 phosphoryla-
tion [Cdc42QL(3): 1.70 6 0.41-fold increase, p value % 0.04
and Cdc42QL(6): 1.50 6 0.30-fold increase, p value % 0.05].
This increased MLC2 phosphorylation appears to be Rho-ki-
nase independent because ROCK inhibitor did not impair it
(data not shown). We also analyzed the speed of amoeboid
moving cells on top of a thick layer of collagen I by tracking
cells with a round morphology. Cells overexpressing Cdc42-
QL migrate significantly faster in an amoeboid manner
[Cdc42QL(3): 0.162 6 0.048 mm/min, p value % 0.04 and
Cdc42QL(6): 0.141 6 0.041 mm/min, p value% 0.04] than con-
trol amoeboid cells (0.079 6 0.017 mm/min). To examine the
role of Cdc42 in invasion, we tested invasion of control and
Cdc42-expressing A375p into a collagen I matrix. Expression
of activated Cdc42 increased tumor cell invasion compared
to control [Figure 3D; Cdc42QL(3): 1.89 6 0.41-fold increase,
p value % 0.02 and Cdc42QL(6): 1.64 6 0.36-fold increase, p
value % 0.04]. These results show that activation of Cdc42
can enhance amoeboid movement and tumor cell invasion.
Cdc42 Effectors N-WASP and Pak2 Promote
Amoeboid Movement
To identify effectors of Cdc42 signaling involved in amoeboid
movement, we used siRNAs to screen a panel of Cdc42 effec-
tors (listed in Figure S6). We found that silencing N-WASP or
Pak2 had similar effects to those caused by silencing
DOCK10. N-WASP knockdown in A375M2 led to the conver-
sion toward a more elongated morphology; the percentage
of elongated cells with two independent siRNAs was increased
to 28%6 5% (p value% 0.01) and 24%6 6% (p value% 0.01),
whereas the control had 14%6 7% elongated cells (Figure 4A
and Figure S7A). WASP-family proteins are key regulatory pro-
teins of the actin cytoskeleton, with N-WASP mediating a direct
connection between Cdc42 and the Arp2/3 complex for actin
polymerization, and N-WASP has been shown to be important
for cell migration [32, 33]. No change in MLC2 phosphorylation
was observed after N-WASP knockdown (data not shown),
suggesting that the Cdc42 effector N-WASP acts separately
from high MLC2 phosphorylation to promote amoeboid
movement.
Pak2 knockdown also led to an increased proportion of
elongated cells (Figures 4C and Figures S7B–S7D). The p21-
activated kinases (Paks) are a family of serine/threonine pro-
tein kinases, some of which, such as Pak2, bind and are stim-
ulated by activated forms of Cdc42 and Rac [34]. Pak2 has
been found to phosphorylate myosin light chain 2 downstream
of Cdc42 and to induce contractility and endothelial cell retrac-
tion [35]. In Pak2 knockdown cell lines, MLC2 phosphorylation
was decreased (Figure 4D, 0.59 6 0.08-fold decrease com-
pared to control, p value % 0.01). To determine whether
activated Pak2 could convert mesechymal-type cells to a
rounded morphology, we overexpressed activated Pak2 in
A375p cells; Figures 4E and 4F show that overexpressing cells
have a rounded amoeboid morphology and increased MLC2
phosphorylation (1.57 6 0.22-fold increase compared tocontrol, p value % 0.05). These data demonstrate that the
Cdc42 effector Pak2 can induce MLC2 phosphorylation and
rounded morphology. To extend these data to another mela-
noma cell line, we examined the effects of knockdown of
DOCK10, N-WASP, and Pak2 in WM1366 cells (Figure S8A).
Similarly to A375M2, knockdown of DOCK10 and the two ef-
fectors increased the proportion of elongated cells
(Figure S8B).
The idea that effectors bind to GEFs to provide selectivity in
signaling is attractive [17]. To study whether there is evidence
for interaction of DOCK10 with downstream effector path-
ways, we examined by coimmunoprecipitation whether
DOCK10 interacts with N-WASP. Figure 4B shows that im-
munoprecipitating DOCK10 with an antibody A310-305A that
recognizes epitopes within amino acids 100–150 of DOCK10
led to the detection of a complex containing DOCK10 and
N-WASP. These results demonstrating that DOCK10 and
N-WASP are in the same complex therefore provide a potential
mechanism for selective signaling from Cdc42 to its effector N-
WASP (Figure 4B). Antibody A310-306A recognizing epitopes
within the C-terminal amino acids 2136–2186 did not immuno-
preciptate a complex with N-WASP, presumably because
these C-terminal epitopes are hidden within the complex and
this antibody therefore only recognizes noncomplexed
DOCK10.
Cdc42 Inhibition Blocks Both Amoeboid andMesenchymal
Movement and Tumor Cell Invasion
The data presented above show that increasing the activity
of Cdc42 induces a mesenchymal-amoeboid transition. To
further investigate the role of Cdc42 in amoeboid cells, we
abrogated Cdc42 signaling in two ways: shRNA stable knock-
down cell lines and dominant-negative Cdc42N17-expressing
cells. Tracking movement of cells with a rounded morphology
showed that in shRNA Cdc42 cells, there was a large decrease
in speed (0.389 6 0.140 mm/min in control compared to
0.133 6 0.043 mm/min in shCdc42 cells, p value % 0.02). In
A375M2 plated on a thick collagen I layer, there is always
a small fraction of elongated cells. In Cdc42 shRNA and
Cdc42N17 cells, the percentage of elongated cells was 1%
6 1% and 4% 6 2% compared with 15% 6 3% and 13% 6
3% for their respective controls (p values% 0.01 and% 0.02)
(Figures 5A and 5C). These results suggest that Cdc42 is re-
quired not only for rounded morphology, but also for elon-
gated-mesenchymal morphology. To further investigate the
role of Cdc42 in elongated-mesenchymal morphology, we
made use of the observation that treatment of A375M2 cells
with a ROCK inhibitor increases the proportion of elongated
cells [5]. Treatment of the scrambled shRNA control or HA-
tag control cells increased the proportion of elongated cells
to 46% 6 9% and 42% 6 4%, respectively, but in the shRNA
Cdc42- or Cdc42N17-expressing cells, the proportion of elon-
gated-mesenchymal cells after ROCK inhibitor treatment was
only 4% 6 2% and 17% 6 6%, respectively (p values% 0.01
and% 0.02) (Figures 5A and 5C and Movies S5 and S6). These
results with blocking Cdc42 signaling are in marked contrast to
those found when expression of the Cdc42 GEF DOCK10 is
abrogated, given that reducing the expression of DOCK10
increases the proportion of elongated cells (Figure 1). These
observations suggest that Cdc42 is required for both(E) Phase-contrast images of A375p cells stably expressing activated Pak2 or control vector plated on a thick layer of collagen I (scale bar represents 100
mm). The inset numbers show the percentage of cells with elongated-mesenchymal morphology (>100 cells scored per experiment, n = 3, mean 6 SEM).
(F) Immunoblots for Pak2 and p-T18-S19-MLC2. One representative experiment out of three is shown.
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(A) A375M2 cells with control vector or shRNA targeting Cdc42 were embedded in collagen I containing ROCK inhibitor or vehicle for 16 hr in IBIDI chambers,
and then time-lapse movies were made for 3 hr. Still pictures are shown at 3 hr; arrows point to elongated cells (scale bar represents 100 mm). The inset
numbers show the percentage of cells with elongated morphology (>100 cells scored per experiment, n = 3, mean 6 SEM).
(B) Immunoblots for Cdc42 and p-T18-S19-MLC2. One representative experiment out of three is shown.
(C) A375M2 control cells or A375M2 cells expressing HA-tagged Cdc42N17 were embedded in collagen I containing ROCK inhibitor or vehicle for 16 hr in
IBIDI chambers, and then time-lapse movies were made for 3 hr. Still pictures are shown from the end of the movies (scale bar represents 100 mm). Arrows
point to elongated cells. The inset numbers show the percentage of cells with elongated morphology (>100 cells scored per experiment, n = 3, mean6 SEM).
(D) Immunoblots for Cdc42 and p-T18-S19-MLC2. One representative experiment out of three is shown.
(E) Invasion into collagen I (n = 3, mean 6 SEM).
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of Cdc42 by DOCK10 specifically acts in rounded morphology
and amoeboid movement. Presumably, other Cdc42 GEFs are
required for mesenchymal morphology and migration.
We have shown that DOCK10 signaling through Cdc42
contributes to actomyosin contractility through Pak2. How-
ever, Rho-Rho-kinase signaling is also known to contribute
to MLC2 phosphorylation; therefore, we examined the relative
contributions of Cdc42 and Rho-kinase signaling. Abrogation
of Cdc42 signaling by RNAi knockdown or dominant-negative
constructs resulted in a decrease of MLC2 phosphorylation
(Figures 5B and 5D; ShCdc42QL: 0.49 6 0.12-fold decrease,
p value % 0.04 and Cdc42N17: 0.58 6 0.17-fold decrease,
p value % 0.05). Although treatment with ROCK inhibitor in
control A375M2 cells did not completely block MLC2 phos-
phorylation, in cell lines in which Cdc42 signaling was blocked,
ROCK inhibitor treatment led to an almost complete disap-
pearance of MLC2 phosphorylation (Figures 5B and 5D;
ShCdc42QL: 0.21 6 0.04-fold decrease, p value % 0.01 and
Cdc42N17: 0.18 6 0.07-fold decrease, p value% 0.01). These
results show that Cdc42 signaling makes multiple contribu-
tions to amoeboid morphology through N-WASP, Pak2, and
MLC2 phosphorylation. Consistent with roles for Cdc42 in
both amoeboid and mesenchymal movement, inhibition of
Cdc42 results in a marked decrease in invasion compared to
control (Figure 5E; ShCdc42: 0.40 6 0.03, p value% 0.01).
Discussion
The mammalian Rho GTPase family contains 22 members, but
there are a much larger number of regulators, with more than
80 GEFs and more than 70 GAPs. An important concept is
that signaling specificity is driven by specific GEFs, which
may localize GTPase activity and lead to association with
specific effectors through scaffolding and docking proteins
[17]. We show that DOCK10 specifically controls Cdc42 activa-
tion in amoeboid motility of melanoma cells because silencing
DOCK10 expression induces an amoeboid-mesenchymal
transition. Interestingly, DOCK10 is implicated in tumor
progression to a metastatic phenotype in other tumor types
because a recent study that shows that DOCK10 is overex-
pressed in aggressive, poorly differentiated papillary thyroid
carcinomas with extensive local invasion or synchronous
distant metastases [36].
DOCK180, the prototypical member of the DOCK family,
activates Rac downstream of integrins and contributes to
mesenchymal movement. It is of interest that we show that a
different member of the family, DOCK10, is linked to Cdc42
and amoeboid movement. DOCK10 is a member of the zizimin
subfamily that may link Cdc42 activation to integrin signaling.
Whether DOCK10 is involved in integrin signaling remains to
be determined, but it is possible that it responds to other
signals because studies from Friedl and coworkers have sug-
gested that amoeboid movement is less dependent on integrin
signaling than mesenchymal-type movement [2, 37]. Future
studies will need to define how these GEFs are regulated, where
they are located, and what are their transmembrane partners.
Our results identify a signaling module consisting of
DOCK10-Cdc42-Pak2 that leads to the phosphorylation of
MLC2. The evidence for this module is based on the following
observations: Knockdown of DOCK10 results in reduced acti-
vation of Cdc42 and phosphorylation of MLC2; blocking
Cdc42 or Pak2 signaling reduces MLC2 phosphorylation,
whereas overexpression of the DOCK10 DHR2 domain oractivated versions of Cdc42 or Pak2 leads to increased
MLC2 phosphorylation. These data present a strong argument
for such a signaling pathway leading to increased actomyosin
contractility, which results in a rounded morphology and
amoeboid movement. Pak2 has been reported to control cell
contractility by direct phosphorylation of MLC2 on serine 19
in endothelial cells [35]. However, we observed a decrease in
both serine-19 and threonine-18 phosphorylation of MLC2
when Pak2 is inhibited. Whether Pak2 initiates the serine-19
phosphorylation followed by the consecutive phosphorylation
of threonine 18 or Pak2 regulates a downstream kinase that is
responsible for the diphosphorylation of MLC2 is not yet clear.
Previous work from this laboratory has shown that the MRCK
family of kinases downstream of Cdc42 can also contribute to
actomyosin contractility through phosphorylation of the
MYPT1-targeting subunit of myosin phosphatase [5], suggest-
ing that Cdc42 has multiple inputs into the regulation of
actomyosin contractility.
Working together with DOCK10-Cdc42-Pak2 signaling in
amoeboid movement is DOCK10-Cdc42-N-WASP signaling.
We show that there is a complex between N-WASP and
DOCK10, supporting the idea that complexes between GEFs
and effectors could provide specificity in signaling [17].
Although silencing N-WASP led to an elongated-mesenchymal
morphology, it was not associated with a reduction in phos-
pho-MLC2, arguing that N-WASP has a different role in amoe-
boid movement. N-WASP is well known to function in actin
assembly [32]. As recently discussed by Fackler and Grosse
[28], how actin is nucleated at the cell cortex during amoeboid
movement is unclear, and our studies suggest that N-WASP
could play such a role. However, Cdc42 signaling to
N-WASP could have other roles, for example, in Golgi-to-ER
protein transport required for amoeboid movement [38].
Our studies identify a Cdc42 activation and signaling path-
way specific to amoeboid movement. However, we show
that Cdc42 is also involved in mesenchymal-type movement.
Abrogating the Cdc42 activator DOCK10 or the Cdc42 effec-
tors Pak2 and N-WASP required for amoeboid movement
leads to an elongated morphology. This argues that there are
specific Cdc42 activation and effector pathways for elongated
morphology and mesenchymal-type movement (see Figure 6).
The identification of these pathways will be of considerable
interest in delineating the differences in Cdc42 signaling path-
ways in the two modes of movement. In mesenchymal-type
motility in 2D, Cdc42 is required for cell polarization toward
the direction of the migration [14]. Additionally, a GEF-Cdc42-
MRCK-mediated pathway leading to phosphorylation of
MLC2 could also provide actomyosin contractility for mesen-
chymal-type movement [5]. Because it is clear that tumor cells
can convert between different modes of movement, to inhibit
tumor cell movement and block metastasis, it may be neces-
sary to simultaneously inhibit both modes of movement or
find components that are common to both pathways.
Experimental Procedures
Materials
Antibodies used include the following: anti-Cdc42 sc-8401 (Santa Cruz Bio-
technology); anti-RhoA sc-418 (Santa Cruz Biotechnology); anti-Pak2
sc1872 (Santa Cruz Biotechnology); anti-DOCK10 A301-305A, A301-306A
(Bethyl Laboratories); anti-Rac1 clone 23A8 (Upstate Biologicals); anti-di-
phospho-Thr18-Ser19-MLC2 (Cell Signaling Technology); anti-b-Tubulin
(Sigma-Aldrich); anti-N-WASP (Abcam), N-WASP 30D10 (Cell Signaling
Technology); and anti-GAPDH (Novus Biologicals). Recombinant glutathi-
one S-transferase (GST)-conjugated Rhotekin and Pak-CRIB were
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1464expressed from pGEX-Rhotekin and pGEX-CRIB. Y-27632 was from Tocris.
H1152 was from Calbiochem (Merck Biosciences).
Cell Culture, Transfection, and Plasmids
A375p and A375M2 cells were a kind gift from R. Hynes (Howard Hughes
Medical Institute, MIT, USA). Cells were routinely maintained in DMEM
containing 10% fetal calf serum. Plasmid transfections were performed
with Amaxa Nucleofector Transfection Reagent in accordance with the
manufacturer’s protocol (Amaxa). Stable cell lines were selected with
G418 (Sigma). Y27632 was used at 10 mM and H1152 at 5 mM.
pCEFL-HA, -Cdc42-QL, and -Cdc42N17 were a kind gift from P. Crespo
(University of Cantabria, Spain). EGFP-C1 was from Clontech,
pRECEIVER-DOCK10DHR2-GFP was from Genecopoeia, and Sure Silenc-
ing shRNA plasmids for DOCK10, Cdc42, and Pak2 were from SuperArray
(KH08298, KH00729N, and KH15598N, respectively). The control and
constitutively active human Pak2 DNA constructs were obtained from
J. Chernoff (Fox Chase Cancer Center, Philadelphia, PA, USA).
siRNA Transfections
siRNA oligonucleotide duplexes used were purchased from Dharmacon.
The GEFs that were targeted are listed in Figure S1. Relevant oligonucleo-
tide sequences are listed in Figure S2. For transfection, 2 3 105 cells were
plated in a 30 mm dish overnight and transfected the next day with 20 nM
SMART pools or individual oligos with Optimem-I and Hiperfect (QIAGEN).
Cells were replated on collagen I in 1% serum at 48 hr and analyzed at
24–48 hr. Sequences of the relevant siRNA and shRNA oligonucleotides
are listed in Figure S2.
Collagen Preparation, Time-Lapse Phase-Contrast Microscopy,
Tracking Assays, and IBIDI Chambers
Fibrillar bovine dermal collagen I was prepared from a 1.7 mg/ml dilution in
DMEM in accordance with the manufacturer’s protocol (Cohesion); 300 ml
was set within a 24-well plate. Time-lapse video microscopy of 24-well plates
was performed in a humidified, CO2-equilibrated chamber with a Diaphot in-
verted microscope (Nikon) equipped with a motorized stage (Prior Scientific)
controlled by Simple PCI software (Compix). Cells were tracked over a period
of 24 hr from 16 hr after setting of the collagen I gel. Cells were tracked in
a semiautomated manner by repeated random selection of cells in initial
frames of time-lapse movies and tracing of migration pathways manually
with Simple PCI analysis software (Compix). Path lengths were measured,
and average cell speeds were derived for each cell by dividing the path
length by the duration of the recording. For evaluation of the percentage of
elongated cells, a cell was considered as elongated when its longest dimen-
sion was twice the shortest and when it showed at least one protrusion. For
analysis of cells embedded in a 3D collagen matrix, cells were mixed with
Figure 6. Schematic Representation of the
Model
Model showing the contributions to amoeboid
motility of DOCK10-Cdc42-N-WASP leading to
actin assembly and DOCK10-Cdc42-Pak2 lead-
ing to actomyosin contractility; the model also
shows a different Cdc42-dependent axis involv-
ing other GEFs and effectors that leads to Rac1
activation and elongated-mesenchymal-type
motility.
collagen I (1.7 mg/ml) and loaded into the cham-
ber (IBIDI). Cells were time-lapsed from 16 hr after
setting of the collagen for 3 hr.
RNA Preparation, Reverse-Transcription,
PCR, and Quantitative Real-Time
One-Step PCR
RNA was prepared with RNAeasy kits (QIAGEN).
cDNAs were made with a First Strand cDNA Syn-
thesis Kit from Amersham. PCRs were performed
with DNA Taq polymerase from Sigma: Melting
step was performed for 1 min at 95c, annealing
step for 30 s at 55c, and elongation step for
30 s at 72c, 28 cycles. The DOCK10 forward
primer was GATCTCTTGGAACCTGAGTC, and the reverse was ATTCC
TCTGGAAGTCCCTTG. For analysis of DOCK10, DOCK9, and DOCK11
expression, Quantitect SYBR Green RT-PCR system (QIAGEN) was used
according to the manufacturer’s instructions.
Immunoprecipitation and Immunoblotting
For immunoprecipitation, cells were grown in 10 cm plates and lysed in 1%
NP-40 buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl [pH 7.4], 25 mM
sodium b-glycerophosphate, 1 mM sodium vanadate, 5 mM NaF, complete
protease inhibitors [Roche 11-873-580-001]). Immunoprecipitations were
carried out at 4C for 3 hr on a rotating wheel. Immune complexes were
precipitated with 25 ml of Protein G Agarose beads (Pierce) for 20 min on a
rotating wheel at 4C. After precipitation, beads were washed at least three
times in 500 ml of lysis buffer and resuspended in Laemmli Sample Buffer
prior to SDS PAGE.
2X Laemmli buffer lysates from a thick collagen I matrix (3 ml of collagen I
preparation were set within a six-well dish) were fractionated by SDS-PAGE
and transferred onto PVDF filters. Immunocomplexes were visualized by the
ECL Plus Western Blotting Detection System (GE Healthcare-Amersham)
with horseradish peroxidase-conjugated secondary antibodies (Sigma) or
by fluorescence with the Li-COR Odyssey (Li-COR Biosciences). Fluores-
cence data from the Li-COR Odyssey were exported into Microsoft Excel.
Invasion Assays
Cells were resuspended in serum-free liquid bovine collagen I at 2.3 mg/ml
for a final concentration of 105 cells/ml. 100 ml aliquots were then dispensed
into black 96-well ViewPlates (Perkin-Elmer) previously coated with BSA.
Plates were then centrifuged at 3003 g to force the cells toward the bottom
of the wells and then incubated in a 10% CO2 tissue culture incubator at 37
c.
Once the collagen I had polymerized, 1% or 5% FCS was added on top of the
collagen to promote invasion of the cells upwards into the collagen. After 24
hr incubation at 37c in 10% CO2, cells were fixed and stained for 2 hr by add-
ing 20% formaldehyde (Sigma) solution containing 5 mg/ml Hoechst 33258,
a nuclear stain (Molecular Probes-Invitrogen); the final formaldehyde con-
centration was 4%. Plates were sealed with black tape to prevent evapora-
tion and exposure to light. Confocal z slices were collected from each well at
40 mm for counting invaded cells and at the bottom of the wells (3 mm) for
counting total cells with an INCELL3000 high-content microscope. Nuclear
staining in each slice was quantified automatically by the INCELL3000 soft-
ware with the Object Intensity module for determination of the percentage of
invasive cells. Samples were run in quadruplicate and averaged.
Pull-Down Assays
For analysis of Cdc42, RhoA, and Rac1 activity, pull-down assays were per-
formed as described previously [39], and where indicated, the extracts were
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1465derived from cells on a thick collagen I matrix (3 ml of collagen preparation
was set within a six-well dish).
Supplemental Data
Supplemental Data include eight figures and six movies and can be found
with this article online at http://www.current-biology.com/cgi/content/full/
18/19/1456/DC1/.
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